TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

25. 7.80 Panackal AA et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44:1740-3. 7.81 Leroy O et al. Epidemiology, management and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009;37:1612-8. 7.82 Viscoli C et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9. 7.83 Kartsonis N et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-23. 7.84 Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:505-35. 7.85 Magill SS et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006;44:529-35. 7.86 Spellberg BJ et al. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-51. 7.87 Kohli R et al. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 2005;19:831-51. 7.88 Smith PB et al. Neonatal candidiasis. Infect Dis Clin North Am 2005;19:603-15. 7.89 Fichtenbaum CJ et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000;30:749-56. 7.90 Saag MS et al. Treatment of fluconazole refractory oropharyngeal candidiasis with itraconazole oral solution in HIV positive patients. AIDS Res Hum Retroviruses 1999;15:1413-7. 7.91 Ally R et al. A randomized, double blind, double dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54. 7.92 Gaitán-Cepeda LA et al. Oral candidosis as a clinical marker of immune failure in patients with HIV/ AIDS on HAART. AIDS Patient Care STDs 2005;19:70-7. 7.93 Epstein JB. Mucositis in the cancer patient and the immunosuppressed host. Infect Dis Clin North Am 2007;21:503-22. 7.94 Sobel JD et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-83. 7.95 Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am 2008;22:637- 52. 7.96 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2006. Morb Mortal Wkly Rep 2006;55(RR-11):1-94. 7.97 Say PJ et al. Difficult to manage vaginitis. Clin Obstet Gynecol 2005;48:753-68. 7.98 Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71. 7.99 Eckert LO. Acute vulvovaginitis. N Engl J Med 2006;355:1244-52. 7.100 Spence D et al. Vaginal discharge. Br Med J 2007;335:1147-51. 7.101 Bassetti M et al. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther 2006;4:875-85. 7.102 Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506. 7.103 Deck DH et al. Pharmacological advances in the treatment of invasive candidiasis. Expert Rev Anti Infect Ther 2006;4:137-49. 7.104 Spellberg BJ et al. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-51. 7.105 Ásmundsdóttir LR et al. Improving survival of patients with candidaemia: analysis of prognostic factors from a long term, nationwide study in Iceland. Scand J Infect Dis 2005;37:111-20. 7.106 Almirante B et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-35. 7.107 Ito JI et al. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005; 40(suppl. 6):S384-91. 7.108 Blyth CC et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123:1360-8. 7.109 Gafter-Gvili A et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008;83:1011-21. 7.110 Morrell M et al. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5. 7.111 Garey KW et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31. 7.112 Charlier C et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410. 7.113 Ruan SY et al. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008;14: 136-40. 7.114 Betts RF et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;48:1676-84. 7.115 Zaoutis TE et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-94. 7.116 Reboli AC et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356: 2472-82. 7.117 Mora-Duarte J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. 7.118 Bennett JE. Echinocandins for candidemia in patients without neutropenia. N Engl J Med 2006;355: 1154-9. 7.119 Kullberg BJ et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non neutropenic patients: a randomised non inferiority trial. Lancet 2005;366:1435-42. 7.120 Nucci M et al. Should vascular catheters be removed from all patients with candidemia? An evidence based review. Clin Infect Dis 2002;34:591-9.
7.121 Walsh TJ et al. All catheter related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600-2. 7.122 Kojic EM et al. Candida infections of medical devices. Clin Microbiol Rev 2004;17:255-67. 7.123 Rodriguez D et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007;13:788-93. 7.124 Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 7.125 Lewis JS. Therapeutic drug monitoring of antifungal agents. Curr Fungal Infect Rep 2009;3:96-102. 7.126 Trifilio S et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. 7.127 Pierrotti LC et al. Fungal endocarditis, 1995-2000. Chest 2002;122:302-10. 7.128 Johnston PG et al. Late recurrent Candida endocarditis. Chest 1991:99:1531-3. 7.129 Muehrcke DD et al. Surgical and long term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995;60:538-43. 7.130 Cornely OA et al. Caspofungin fot the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007;60:363-9. 7.131 Jiménez-Expósito MJ et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004;39:e70-3. 7.132 Rajendram R et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis 2005;40:e72-4. 7.133 Ellis ME et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50-62. 7.134 Keynan Y et al. Fungal endocarditis. Curr Fungal Infect Rep 2007;1:25-32. 7.135 Baddley JW et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519-29. 7.136 Zaoutis TE et al. Risk factors for disseminated candidiasis in children with candidaemia. Pediatr Infect Dis J 2004;23:635-41. 7.137 Martίnez-Vázquez C et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998;27:1130-3. 7.138 Breit SM et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-40. 7.139 Darling K et al. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). J Infect 2000;40:92-4. 7.140 Martίnez-Vázquez C et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998;27:1130-3. 7.141 Akler ME et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20:657-64. 7.142 Sallam A et al. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther 2006;4:675-85. 7.143 Shah CP et al. Ocular candidiasis: a review. Br J Ophthalmol 2008;92:466-8. 7.144 Wang AY et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000;36:1183-92. 7.145 Piraino B et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25:107-31. 7.146 Drew RH et al. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 2005;40:1465-70. 7.147 Sobel JD et al. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007;44: e46-9. 7.148 Kauffman CA et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000;30:14-8. 7.149 Malani AN et al. Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther 2007;5:277-84. 7.150 Lundstrom T et al. Nosocomial candiduria: a review. Clin Infect Dis 2001;32:1602-7. 7.151 Kauffman CA. Candiduria. Clin Infect Dis 2005;41(suppl. 6):S371-6. 7.152 Achkar JM et al. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010;23:376-81. 7.153 Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol 2009; 34:849-54. 7.154 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.155 Minotto R et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol 2001;44:585-92. 7.156 Parish JM et al. Coccidoidomycosis. Mayo Clin Proc 2008;83:343-9. 7.157 Saubolle MA et al. Epidemiological, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 2007;45:26-30. 7.158 Anstead GM et al. Coccidioidomycosis. Infect Dis Clin North Am 2006;20:621-43. 7.159 Galgiani JN et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23. 7.160 Blair JE et al. Coccidioidomycosis in elderly persons. Clin Infect Dis 2008;47:1513-8. 7.161 Chiller TM et al. Coccidioidomycosis. Infect Dis Clin North Am 2003;17:41-57. 7.162 Valdivia L et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006;12:958-62. 7.163 Masannat FY et al. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis 2010;50:1-7. 7.164 Blair JE et al. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 165:113-7. 7.165 Bergstrom L et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 2004;50:1959-66. 7.166 Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008;21:415-20. 7.167 Blair JE et al. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001;33:1536-44. 7.168 Braddy CM et al. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant 2006;6:340-5. 7.169 Adam RD et al. The spectrum and presentation of disseminated coccidioidomycosis. Am J Med 2009;122:770-7. 7.170 Galgiani JN et al. Comparison of oral fluconazole and itraconazole for progressive, non meningeal coccidioidomycosis. A randomized, double blind trial. Ann Intern Med 2000;133:676-86.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47: 7.38 Meersseman W et al. Invasive a
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?